Kemp Dolliver
Stock Analyst at Brookline Capital
(0.60)
# 3,944
Out of 4,944 analysts
17
Total ratings
38.46%
Success rate
-18.13%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RADX Radiopharm Theranostics | Initiates: Buy | $18 | $5.30 | +239.62% | 1 | Jul 21, 2025 | |
| LSTA Lisata Therapeutics | Maintains: Buy | $20 → $32 | $2.66 | +1,101.02% | 1 | Jul 15, 2025 | |
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $8.51 | +99.76% | 1 | Dec 5, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $6.59 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.73 | +393.83% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.11 | +1,606.16% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $2.13 | +1,374.18% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $8.90 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $53.79 | +85.91% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.19 | +2,502.01% | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $25 | $3.20 | +681.25% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.14 | +264.79% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.85 | +846.63% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $0.84 | +572.62% | 1 | Feb 2, 2022 |
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $5.30
Upside: +239.62%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20 → $32
Current: $2.66
Upside: +1,101.02%
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $8.51
Upside: +99.76%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $6.59
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.73
Upside: +393.83%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.11
Upside: +1,606.16%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $2.13
Upside: +1,374.18%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $8.90
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $53.79
Upside: +85.91%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.19
Upside: +2,502.01%
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $3.20
Upside: +681.25%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $5.14
Upside: +264.79%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.85
Upside: +846.63%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $0.84
Upside: +572.62%